The Q1 beat and FY guidance raise confirm strong execution and accelerating international adoption. However, the stock has historically sold off after earnings beats (avg -15.89% at T+20 on last two reports). Watch for the broader Omnipod 5 algorithm launch and EVOLVE pivotal study enrollment as catalysts. The medical device correction is a modest overhang but appears contained.
Price Chart
Executive Summary
Insulet reported Q1 2026 revenue of $761.7M (+33.9% YoY, +30.1% cc), exceeding the high end of its 25%-27% cc guidance, and GAAP diluted EPS of $1.30 (vs $0.50 YoY). The company raised its full-year 2026 total revenue growth guidance to 21%-23% cc (from 20%-22% cc), driven by strong Omnipod 5 adoption and international expansion. The beat and guidance raise are positive, but the stock has historically not reacted well to earnings beats, and the voluntary medical device correction in March 2026 introduces a modest headwind.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $761.7M (+33.9% YoY, +30.1% cc) exceeded the high end of 25%-27% cc guidance
- Total Omnipod revenue of $758.4M (+36.9% YoY, +33.0% cc); International Omnipod revenue surged 59.4% (+45.2% cc)
- GAAP diluted EPS of $1.30 vs $0.50 YoY; Adjusted diluted EPS of $1.42 vs $1.02 YoY (+39.7%)
- Raised FY 2026 total revenue growth guidance to 21%-23% cc (from prior 20%-22% cc); maintained 100bps adjusted operating margin expansion and 25% adjusted EPS growth targets
- Voluntary medical device correction in March 2026 incurred $11.7M in estimated warranty costs (included in cost of revenue)
- Repurchased 1.25 million shares of common stock in Q1
- Operating cash flow of $113.8M vs $63.8M YoY; Free cash flow of $89.5M vs $51.6M YoY
Financial Impact
Revenue beat of ~$31.6M vs consensus ($761.7M actual vs $730.1M est); GAAP EPS beat of $0.11 vs consensus ($1.30 actual vs $1.19 est)
Risk Factors
- Voluntary medical device correction could lead to further warranty costs or regulatory scrutiny
- International growth faces currency headwinds (14.2% currency impact in Q1) and geopolitical risks (Iran conflict mentioned)
- Competitive pressure from other AID systems (Tandem, Medtronic) could slow market share gains
- Stock has historically underperformed after earnings beats, suggesting market may be pricing in higher expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001145197-26-000100 |
| Document: podd-20260506.htm | 0001145197-26-000100 |
| Document: 0001145197-26-000100-index-headers.html | 0001145197-26-000100 |
| Document: 0001145197-26-000100-index.html | 0001145197-26-000100 |
| Document: 0001145197-26-000100.txt | 0001145197-26-000100 |
| 8-K Data (Synthetic) | 0001145197-26-000100 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $132.30 $148.14 | ▲ +11.97% | ▲ +12.57% | $131.69 (−0.46%) |
Aug 3, 2026 8w ago | Press Release | $169.70 $148.66 | ▲ +12.40% | ▲ +13.64% | $131.69 (+22.40%) |
Jul 30, 2026 9w ago | Press Release | $165.68 $143.41 | ▲ +13.44% | ▲ +17.41% | $131.69 (+20.52%) |
Jul 24, 2026 10w ago | Institutional Cluster | $163.26 $147.92 | ▲ +9.39% | ▲ +13.02% | $131.69 (+19.34%) |
Jul 13, 2026 11w ago | Press Release | $159.12 $144.70 | ▼ −9.06% | ▼ −11.55% | $131.69 (−17.24%) |
Jul 3, 2026 12w ago | Press Release | $159.77 $165.35 | ▼ −3.49% | ▼ −4.06% | $131.69 (+17.58%) |
May 28, 2026 18w ago | Court Ruling | $141.98 $153.82 | ▼ −8.34% | ▼ −11.03% | $131.69 (+7.25%) |
May 6, 2026 21w ago | 8-K | $150.52 $143.30 | ▼ −4.80% | ▼ −7.58% | $131.69 (−12.51%) |
Mar 4, 2026 30w ago | 8-K | $240.55 $204.04 | ▼ −15.18% | ▼ −11.39% | $131.69 (−45.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access